Functional Dyspepsia (FD) is a common affliction in western countries effecting approximately 25% of the population. Due to its heterogeneous pathogenesis, effective therapeutics are limited. Mosapride, a serotonin receptor agonist with enterokinetic properties, has been evaluated for treating dyspeptic symptoms in a limited number of clinical trials. Most trials found mosapride to be as effective as other commonly used treatments for FD including histamine receptor blockers (H2RAs), and the results of the only randomized double-blind placebo-controlled trial to date found mosapride to be no more effective than placebo. These studies were limited by suboptimal study design and performed prior to sub-classification of FD sub-types as defined by Rome III. Therefore, there is currently inadequate data to comment on the efficacy of mosapride for treating FD. Larger placebo controlled trials differentiating dyspeptic patients by primary symptom associations are necessary.

Discussion
No comments yet...Be the first to comment.

 CONNOTEA  CITEULIKE FACEBOOK LINKED IN